Malignant Ascites

Abstract

Malignant ascites negatively impacts patient's quality of life and has significant impact on the health care resources. Majority of management guidelines are based on systemic reviews that have predominately relied on retrospective data. Therefore, there is lack of high-level evidence-based studies. In this review, the etiologies, pathophysiology, and various treatment methods including diuretic therapy, large volume paracentesis, indwelling catheter placement, peritoneovenous shunt, transjugular intrahepatic portosystemic shunt, and other available novel and/or experimental options are reviewed.

Keywords

malignant ascites - palliation - diuretic - paracentesis - peritoneovenous shunt - TIPS - intraperitoneal chemotherapy

Publikationsverlauf

Eingereicht: 12. Juni 2020

Angenommen: 30. Juli 2020

Artikel online veröffentlicht:
22. September 2020

• References

• 1 Ayantunde AA, Parsons SL. Pattern and prognostic factors in patients with malignant ascites: a retrospective study. Ann Oncol 2007; 18 (05) 945-949
• 2 Kipps E, Tan DS, Kaye SB. Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research. Nat Rev Cancer 2013; 13 (04) 273-282
• 3 Narayanan G, Pezeshkmehr A, Venkat S, Guerrero G, Barbery K. Safety and efficacy of the PleurX catheter for the treatment of malignant ascites. J Palliat Med 2014; 17 (08) 906-912
• 4 Meier M, Mortensen FV, Madsen HH. Malignant ascites in patients with terminal cancer is effectively treated with permanent peritoneal catheter. Acta Radiol Open 2015; 4 (07) 2058460115579934
• 5 Ringenberg QS, Doll DC, Loy TS, Yarbro JW. Malignant ascites of unknown origin. Cancer 1989; 64 (03) 753-755
• 6 Aslam N, Marino CR. Malignant ascites: new concepts in pathophysiology, diagnosis, and management. Arch Intern Med 2001; 161 (22) 2733-2737
• 7 Yarmohammadi H, Schilsky J, Durack JC. et al. Treatment of chylous ascites with peritoneovenous shunt (Denver shunt) following retroperitoneal lymph node dissection in patients with urologic malignancies: update of efficacy and predictors of complications. J Urol 2020; (epub ahead of print)
• 8 Adam RA, Adam YG. Malignant ascites: past, present, and future. J Am Coll Surg 2004; 198 (06) 999-1011
• 9 European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 2010; 53 (03) 397-417
• 10 Fleming ND, Alvarez-Secord A, Von Gruenigen V, Miller MJ, Abernethy AP. Indwelling catheters for the management of refractory malignant ascites: a systematic literature overview and retrospective chart review. J Pain Symptom Manage 2009; 38 (03) 341-349
• 11 Pockros PJ, Esrason KT, Nguyen C, Duque J, Woods S. Mobilization of malignant ascites with diuretics is dependent on ascitic fluid characteristics. Gastroenterology 1992; 103 (04) 1302-1306
• 12 Runyon BA. AASLD. Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012. Hepatology 2013; 57 (04) 1651-1653
• 13 Angeli P, Fasolato S, Mazza E. et al. Combined versus sequential diuretic treatment of ascites in non-azotaemic patients with cirrhosis: results of an open randomised clinical trial. Gut 2010; 59 (01) 98-104
• 14 Bernardi M. Optimum use of diuretics in managing ascites in patients with cirrhosis. Gut 2010; 59 (01) 10-11
• 15 Keen A, Fitzgerald D, Bryant A, Dickinson HO. Management of drainage for malignant ascites in gynaecological cancer. Cochrane Database Syst Rev 2010; (01) CD007794
• 16 Easson AM, Bezjak A, Ross S, Wright JG. The ability of existing questionnaires to measure symptom change after paracentesis for symptomatic ascites. Ann Surg Oncol 2007; 14 (08) 2348-2357
• 17 Harding V, Fenu E, Medani H. et al. Safety, cost-effectiveness and feasibility of day case paracentesis in the management of malignant ascites with a focus on ovarian cancer. Br J Cancer 2012; 107 (06) 925-930
• 18 Becker G, Galandi D, Blum HE. Malignant ascites: systematic review and guideline for treatment. Eur J Cancer 2006; 42 (05) 589-597
• 19 Fischer DS. Abdominal paracentesis for malignant ascites. Arch Intern Med 1979; 139 (02) 235
• 20 Stokes LS. Percutaneous management of malignant fluid collections. Semin Intervent Radiol 2007; 24 (04) 398-408
• 21 Kurtz RC, Bronzo RL. Does spontaneous bacterial peritonitis occur in malignant ascites?. Am J Gastroenterol 1982; 77 (03) 146-148
• 22 Patel IJ, Davidson JC, Nikolic B. Standards of Practice Committee, with Cardiovascular and Interventional Radiological Society of Europe (CIRSE) Endorsement, Standards of Practice Committee of the Society of Interventional Radiology. et al. Addendum of newer anticoagulants to the SIR consensus guideline. J Vasc Interv Radiol 2013; 24 (05) 641-645
• 23 McNamara P. Paracentesis--an effective method of symptom control in the palliative care setting?. Palliat Med 2000; 14 (01) 62-64
• 24 Ross GJ, Kessler HB, Clair MR, Gatenby RA, Hartz WH, Ross LV. Sonographically guided paracentesis for palliation of symptomatic malignant ascites. AJR Am J Roentgenol 1989; 153 (06) 1309-1311
• 25 Cavazzoni E, Bugiantella W, Graziosi L, Franceschini MS, Donini A. Malignant ascites: pathophysiology and treatment. Int J Clin Oncol 2013; 18 (01) 1-9
• 26 Bohn KA, Ray Jr CE. Repeat large-volume paracentesis versus tunneled peritoneal catheter placement for malignant ascites: a cost-minimization study. AJR Am J Roentgenol 2015; 205 (05) 1126-1134
• 27 Lee A, Lau TN, Yeong KY. Indwelling catheters for the management of malignant ascites. Support Care Cancer 2000; 8 (06) 493-499
• 28 Knight JA, Thompson SM, Fleming CJ. et al. Safety and effectiveness of palliative tunneled peritoneal drainage catheters in the management of refractory malignant and non-malignant ascites. Cardiovasc Intervent Radiol 2018; 41 (05) 753-761
• 29 Stukan M. Drainage of malignant ascites: patient selection and perspectives. Cancer Manag Res 2017; 9: 115-130
• 30 Wong BC, Cake L, Kachuik L, Amjadi K. Indwelling peritoneal catheters for managing malignancy-associated ascites. J Palliat Care 2015; 31 (04) 243-249
• 31 Courtney A, Nemcek Jr AA, Rosenberg S, Tutton S, Darcy M, Gordon G. Prospective evaluation of the PleurX catheter when used to treat recurrent ascites associated with malignancy. J Vasc Interv Radiol 2008; 19 (12) 1723-1731
• 32 Lungren MP, Kim CY, Stewart JK, Smith TP, Miller MJ. Tunneled peritoneal drainage catheter placement for refractory ascites: single-center experience in 188 patients. J Vasc Interv Radiol 2013; 24 (09) 1303-1308
• 33 Rosenberg S, Courtney A, Nemcek Jr AA, Omary RA. Comparison of percutaneous management techniques for recurrent malignant ascites. J Vasc Interv Radiol 2004; 15 (10) 1129-1131
• 34 Kaya A, Nas OF, Erdogan C. Tunneled peritoneal catheter placement in palliation of malignant ascites: a study with two different types of catheters. BioMed Res Int 2019; 2019: 4132396
• 35 Gilbert CR, Lee HJ, Skalski JH. et al. The use of indwelling tunneled pleural catheters for recurrent pleural effusions in patients with hematologic malignancies: a multicenter study. Chest 2015; 148 (03) 752-758
• 36 Maleux G, Indesteege I, Laenen A, Verslype C, Vergote I, Prenen H. Tenckhoff tunneled peritoneal catheter placement in the palliative treatment of malignant ascites: technical results and overall clinical outcome. Radiol Oncol 2016; 50 (02) 197-203
• 37 Yarmohammadi H, Brody LA, Erinjeri JP. et al. Therapeutic application of percutaneous peritoneovenous (Denver) shunt in treating chylous ascites in cancer patients. J Vasc Interv Radiol 2016; 27 (05) 665-673
• 38 Bratby MJ, Hussain FF, Lopez AJ. Radiological insertion and management of peritoneovenous shunt. Cardiovasc Intervent Radiol 2007; 30 (03) 415-418
• 39 Tomiyama K, Takahashi M, Fujii T. et al. Improved quality of life for malignant ascites patients by Denver peritoneovenous shunts. Anticancer Res 2006; 26 3B, 3b 2393-2395
• 40 Yarmohammadi H, Getrajdman GI. Symptomatic fluid drainage: peritoneovenous shunt placement. Semin Intervent Radiol 2017; 34 (04) 343-348
• 41 Sugawara S, Sone M, Arai Y. et al. Radiological insertion of Denver peritoneovenous shunts for malignant refractory ascites: a retrospective multicenter study (JIVROSG-0809). Cardiovasc Intervent Radiol 2011; 34 (05) 980-988
• 42 Seike M, Maetani I, Sakai Y. Treatment of malignant ascites in patients with advanced cancer: peritoneovenous shunt versus paracentesis. J Gastroenterol Hepatol 2007; 22 (12) 2161-2166
• 43 Wallace M, Swaim M. Transjugular intrahepatic portosystemic shunts through hepatic neoplasms. J Vasc Interv Radiol 2003; 14 (04) 501-507
• 44 Chen BS, Wong SHC, Hawkins S, Huggins L. Permanent peritoneal ports for the management of recurrent malignant ascites: a retrospective review of safety and efficacy. Intern Med J 2018; 48 (12) 1524-1528
• 45 Monsky WL, Yoneda KY, MacMillan J. et al. Peritoneal and pleural ports for management of refractory ascites and pleural effusions: assessment of impact on patient quality of life and hospice/home nursing care. J Palliat Med 2009; 12 (09) 811-817
• 46 Facchiano E, Risio D, Kianmanesh R, Msika S. Laparoscopic hyperthermic intraperitoneal chemotherapy: indications, aims, and results: a systematic review of the literature. Ann Surg Oncol 2012; 19 (09) 2946-2950
• 47 Hodge C, Badgwell BD. Palliation of malignant ascites. J Surg Oncol 2019; 120 (01) 67-73
• 48 de Mestier L, Volet J, Scaglia E, Msika S, Kianmanesh R, Bouché O. Is palliative laparoscopic hyperthermic intraperitoneal chemotherapy effective in patients with malignant hemorrhagic ascites?. Case Rep Gastroenterol 2012; 6 (01) 166-170
• 49 Matsusaki K, Orihashi K. Feasibility, efficacy, and safety of cell-free and concentrated ascites reinfusion therapy (KM-CART) for malignant ascites. Artif Organs 2020; (epub ahead of print)
• 50 Ito T, Hanafusa N, Iwase S. et al. Effects of cell-free and concentrated ascites reinfusion therapy (CART) on symptom relief of malignancy-related ascites. Int J Clin Oncol 2015; 20 (03) 623-628
• 51 Tsikouras P, Tsagias N, Pinidis P. et al. The contribution of catumaxomab in the treatment of malignant ascites in patients with ovarian cancer: a review of the literature. Arch Gynecol Obstet 2013; 288 (03) 581-585
• 52 Rozenblit GN, Del Guercio LR, Rundback JH, Poplausky MR, Lebovics E. Peritoneal-urinary drainage for treatment of refractory ascites: a pilot study. J Vasc Interv Radiol 1998; 9 (06) 998-1005
• 53 Fotopoulou C, Berg T, Hausen A. et al. Continuous low flow ascites drainage through the urinary bladder via the Alfapump system in palliative patients with malignant ascites. BMC Palliat Care 2019; 18 (01) 109